Ocrelizumab accepted for EMA review
Ocrelizumab accepted for EMA review
Roche has announced that the European Medicines Agency (EMA) has validated the company’s Marketing Authorisation Application (MAA) of ocrelizumab for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS) in the European Union (EU)...Read more - http://www.ms-uk.org/MSnews
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 10723 Views
-
Last post by NHE
-
- 0 Replies
- 1013 Views
-
Last post by NHE
-
- 0 Replies
- 1813 Views
-
Last post by frodo
-
- 0 Replies
- 1147 Views
-
Last post by frodo
-
- 0 Replies
- 1940 Views
-
Last post by NHE
-
- 0 Replies
- 1624 Views
-
Last post by frodo
-
- 0 Replies
- 1161 Views
-
Last post by NHE
-
- 1 Replies
- 1570 Views
-
Last post by frodo
-
- 0 Replies
- 2199 Views
-
Last post by NHE